Get the Stockscreener App
131.77
0.60%
-0.80
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $131.77, with a volume of 2.06M.
It is down -0.60% in the last 24 hours and down -1.46% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$132.57
Open:
$132
24h Volume:
2.06M
Relative Volume:
0.34
Market Cap:
$229.29B
Revenue:
$43.11B
Net Income/Loss:
$13.94B
P/E Ratio:
16.48
EPS:
7.9963
Net Cash Flow:
$6.78B
1W Performance:
-1.47%
1M Performance:
-1.46%
6M Performance:
+3.86%
1Y Performance:
+13.49%
1-Day Range:
$131.17
$132.76
1-Week Range:
$131.17
$135.12
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
131.74 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.51 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
366.03 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.90 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Ex-Dividend Reminder: Abbott Laboratories, AbbVie and ARMOUR Residential REIT - Nasdaq
Vest Financial LLC Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
MOKAN Wealth Management Inc. Has $2.99 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Welch Group LLC Grows Position in Abbott Laboratories $ABT - MarketBeat
Pathway Financial Advisors LLC Sells 3,588 Shares of Abbott Laboratories $ABT - MarketBeat
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Volatility clustering patterns for Abbott LaboratoriesWeekly Trend Report & Fast Gain Stock Tips - newser.com
Mitchell Sinkler & Starr PA Sells 70,137 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Natural Investments LLC - MarketBeat
Abbott Laboratories $ABT Stock Holdings Increased by Fifth Third Wealth Advisors LLC - MarketBeat
Cwm LLC Raises Position in Abbott Laboratories $ABT - MarketBeat
DSM Capital Partners LLC Sells 81,763 Shares of Abbott Laboratories $ABT - MarketBeat
Johnson Investment Counsel Inc. Lowers Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Raised by Concurrent Investment Advisors LLC - MarketBeat
Sivik Global Healthcare LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Those who invested in Abbott Laboratories (NYSE:ABT) three years ago are up 39% - Yahoo Finance
Benchmark Initiates Coverage on Abbott Laboratories (NYSE:ABT) - MarketBeat
PDS Planning Inc Increases Stake in Abbott Laboratories $ABT - MarketBeat
Wealthstar Advisors LLC Decreases Position in Abbott Laboratories $ABT - MarketBeat
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
McKinley Carter Wealth Services Inc. Purchases 15,362 Shares of Abbott Laboratories $ABT - MarketBeat
Ramirez Asset Management Inc. Increases Position in Abbott Laboratories $ABT - MarketBeat
Aberdeen Group plc Purchases 81,094 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Trimmed by Coerente Capital Management - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Eastern Bank - MarketBeat
Horizon Bancorp Inc. IN Has $781,000 Stake in Abbott Laboratories $ABT - MarketBeat
Benchmark Initiates Coverage of Abbott Laboratories (ABT) with Buy Recommendation - Nasdaq
Abbott Laboratories (ABT): Exploring Valuation After Recent Shareholder Returns and Growth Prospects - simplywall.st
Abbott gets FDA breakthrough nod for dual-energy ablation catheter - MassDevice
Abbott is a steady Medtech company in an unsteady world, says Benchmark - Investing.com
Therapeutic Drug Monitoring (TDM) Market Size Expected to Reach USD 2.80 Bn by 2034 - GlobeNewswire Inc.
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus - The Globe and Mail
US Bancorp DE Has $390.37 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings - Nasdaq
Abbott (ABT) Receives Buy Rating with Bullish Outlook - GuruFocus
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Abbott Laboratories: Diversified Growth and Strategic Investments Justify Buy Rating - TipRanks
Abbott Laboratories $ABT Shares Bought by Callan Family Office LLC - MarketBeat
Can Abbott Laboratories Deliver On Q3 Earnings Expectations? - RTTNews
Is Abbott Laboratories (ABL) stock cheap by valuation metrics2025 Earnings Surprises & Daily Entry Point Trade Alerts - newser.com
Pedialyte class action claims ‘healthy’ hydration drinks contain harmful artificial sweetener - Class Action Lawsuits
Abbott adds Laralab AI-based cardiac imaging tech - MassDevice
Abbott Laboratories: There May Be A Surge Coming Next Week (Earnings Preview) (ABT) - Seeking Alpha
First Merchants Corp Sells 4,988 Shares of Abbott Laboratories $ABT - MarketBeat
Maryland State Retirement & Pension System Has $11.45 Million Position in Abbott Laboratories $ABT - MarketBeat
Fluent Financial LLC Has $4.34 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Kingswood Wealth Advisors LLC Has $1.12 Million Holdings in Abbott Laboratories $ABT - MarketBeat
How Abbott Laboratories stock compares to growth peersJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
Abbott Labs Is UBS’s Top MedTech Value Play For Growth - Finimize
Abbott Laboratories (NYSE:ABT) Given "Buy (B)" Rating at Weiss Ratings - MarketBeat
UBS reiterates Buy rating on Abbott Labs stock, citing undervalued growth - Investing.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.09%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):